Literature DB >> 19737042

Cognitive assessment of a trekking expedition to 5100 m: a comparison of computerized and written testing methods.

Gregory A Harris1, Jennifer Cleland, Alex Collie, Paul McCrory.   

Abstract

OBJECTIVE: To assess a typical commercial trekking cohort for cognitive impairment after gradual ascent to 5100 m.
METHODS: We performed a prospective, controlled, repeated-measures study within a trekking expedition to Nepal. A sample of expedition participants was studied; 36 were enrolled and 26 completed all testing. Additional normative data were sourced from sea level studies. Participants underwent cognitive assessment before travel with written, verbal, and computerized tests, then within 24 hours of arrival at 5100 m after an 18-day ascent from 400 m. Changes in performance in 6 written and 7 computerized tests were analyzed at an individual and group level using paired t tests. Effect size analysis was performed for individual performance.
RESULTS: No individual demonstrated significant cognitive impairment at 5100 m. The subject group performed significantly better than the normative population in 3 of the 6 written tests. The group performed worse at 5100 m in 1 written test (digit span forwards, P < .01) and better in 2 written (digit-symbol substitution, P < .01; trail-making test, part B, P < .05) and 1 computerized test (monitoring test reaction time, P < .01). Performance was more variable in the written than the computerized tests.
CONCLUSIONS: Gradual ascent to high altitude causes no significant cognitive impairment in the majority of individuals. Computerized testing produced less variable results than written testing, but logistical difficulties are likely to preclude widespread use of such technology in the field.

Entities:  

Mesh:

Year:  2009        PMID: 19737042     DOI: 10.1580/08-WEME-OR-261R.1

Source DB:  PubMed          Journal:  Wilderness Environ Med        ISSN: 1080-6032            Impact factor:   1.518


  6 in total

1.  Caudwell Xtreme Everest: A prospective study of the effects of environmental hypoxia on cognitive functioning.

Authors:  Konstadina Griva; Jan Stygall; Mark H Wilson; Daniel Martin; Denny Levett; Kay Mitchell; Monty Mythen; Hugh E Montgomery; Mike P Grocott; Golnar Aref-Adib; Mark Edsell; Tracie Plant; Chris Imray; Debbie Cooke; Jane Harrington; Maryam Khosravi; Stanton P Newman
Journal:  PLoS One       Date:  2017-03-27       Impact factor: 3.240

2.  Goodenough-Harris Drawing a Man Test (GHDAMT) as a Substitute of Ages and Stages Questionnaires (ASQ2) for Evaluation of Cognition.

Authors:  Nasrin Baraheni; Seifollah Heidarabady; Shahrooz Nemati; Morteza Ghojazadeh
Journal:  Iran J Child Neurol       Date:  2018

3.  Cognitive function and mood at high altitude following acclimatization and use of supplemental oxygen and adaptive servoventilation sleep treatments.

Authors:  Erica C Heinrich; Matea A Djokic; Dillon Gilbertson; Pamela N DeYoung; Naa-Oye Bosompra; Lu Wu; Cecilia Anza-Ramirez; Jeremy E Orr; Frank L Powell; Atul Malhotra; Tatum S Simonson
Journal:  PLoS One       Date:  2019-06-12       Impact factor: 3.240

4.  Aerobic metabolism on muscle contraction in porcine iris sphincter.

Authors:  Hidenori Kanda; Takeharu Kaneda; Asami Kato; Takuya Yogo; Yasuji Harada; Yasusi Hara; Norimoto Urakawa; Kazumasa Shimizu
Journal:  J Vet Med Sci       Date:  2016-08-09       Impact factor: 1.267

5.  The influence of hypoxia and prolonged exercise on attentional performance at high and extreme altitudes: A pilot study.

Authors:  Mirjam Limmer; Petra Platen
Journal:  PLoS One       Date:  2018-10-03       Impact factor: 3.240

6.  Effects on Cognitive Functioning of Acute, Subacute and Repeated Exposures to High Altitude.

Authors:  Matiram Pun; Veronica Guadagni; Kaitlyn M Bettauer; Lauren L Drogos; Julie Aitken; Sara E Hartmann; Michael Furian; Lara Muralt; Mona Lichtblau; Patrick R Bader; Jean M Rawling; Andrea B Protzner; Silvia Ulrich; Konrad E Bloch; Barry Giesbrecht; Marc J Poulin
Journal:  Front Physiol       Date:  2018-08-21       Impact factor: 4.566

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.